Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.298 EUR | -12.87% | -4.49% | -27.32% |
05-15 | Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M | MT |
04-30 | Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | 25.74M 27.91M 38.04M | Sales 2023 | 32.25M 34.97M 47.66M | Capitalization | 25.59M 27.75M 37.81M |
---|---|---|---|---|---|
Net income 2022 | -44M -47.72M -65.02M | Net income 2023 | - 0 0 | EV / Sales 2022 | 3.59 x |
Net cash position 2022 | 4.88M 5.29M 7.2M | Net cash position 2023 | 1.93M 2.1M 2.86M | EV / Sales 2023 | 0.73 x |
P/E ratio 2022 |
-1.98
x | P/E ratio 2023 |
-40.1
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 32.4% |
Latest transcript on Biofrontera
1 day | -12.87% | ||
1 week | -4.49% | ||
Current month | -17.68% | ||
1 month | -11.83% | ||
3 months | -27.49% | ||
6 months | -34.65% | ||
Current year | -27.32% |
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 55 | 22-09-11 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 21-12-13 | |
Heikki Lanckriet
BRD | Director/Board Member | 46 | 21-12-13 |
Helge Lubenow
CHM | Chairman | 56 | 21-12-13 |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- B8FK Stock
- B8F Stock